NEXEL
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21 Wangsan-ro Dongdaemun-gu, Seoul, Seou...Phone Number
+82 220888884Website
www.nexel.co.krRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About NEXEL
NEXEL is a biotechnology company commercializing "Korea's first" induced pluripotent stem cell (iPSC)-derived cell products. NEXEL partners with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the most accurate product quality data for cardiac safety. NEXEL expertise in iPSC-derived cardiomyocyte-based cardiac safety testing with precision, pace and passion, enabling our customers to power ahead safely. NEXEL has established NEXEL USA, Inc. in November 2012 to serve the needs of the life sciences research community and planned the construction of a 20,000 ft2 biomanufacturing facility nearby Seattle, Washington.Explore more
NEXEL Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NEXEL your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at NEXEL
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when NEXEL launches new products
NEXEL, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if NEXEL is spiking on competitors!
Click to see if NEXEL had a recent Job posting/layoffs
Check if NEXEL has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on NEXEL recently announced quarterly report
Funding: Get notified immidiatlly once NEXEL has new funding data
Recommended Actions
Find VP level buyers at NEXEL
Find more new buyers
Company Profile Activity
Activity Insights
NEXEL is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NEXEL is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NEXEL.
NEXEL Tech Stack
A closer look at the technologies used by NEXEL
See more technologies
NEXEL News & Media
Celogics License in NEXEL's Cardiosight-S for Global Distribution
SEATTLE--(BUSINESS WIRE)--Celogics, a U.S.-based manufacturer of human iPSC-derived cell products for therapeutics development and life sciences research, today announced the exclusive licensing of NEXEL’s Cardiosight-S, a leading iPSC-derived cardiomyocyte product line. At the same time, Celogics announced the planned construction of a 20,000 ft2 biomanufacturing facility nearby Seattle, Washington. This facility will be used to manufacture high-quality iPSC-derived cell products utilizing theCuri Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products
SEATTLE & SEOUL, South Korea--(BUSINESS WIRE)-- #biotech--Curi Bio and NEXEL Announce Celogics, Joint Venture Based in Seattle to Develop Leading iPSC-derived Cell Products for Drug Discovery & Safety Testing
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NEXEL
Sign Up For FreeTo access detailed company insights
NEXEL is a biotechnology company commercializing "Korea's first" induced pluripotent stem cell (iPSC)-derived cell products. NEXEL partners with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the most accurate product quality data for cardiac safety. NEXEL expertise in iPSC-derived card... Read More
